Your browser is no longer supported. Please, upgrade your browser.
Settings
VRX Valeant Pharmaceuticals International, Inc. daily Stock Chart
VRX [NYSE]
Valeant Pharmaceuticals International, Inc.
Index- P/E- EPS (ttm)-6.49 Insider Own2.30% Shs Outstand344.86M Perf Week-0.25%
Market Cap5.58B Forward P/E3.32 EPS next Y4.87 Insider Trans-30.44% Shs Float332.27M Perf Month15.65%
Income-2256.30M PEG- EPS next Q1.22 Inst Own66.80% Short Float10.72% Perf Quarter-9.25%
Sales10.01B P/S0.56 EPS this Y-133.00% Inst Trans20.42% Short Ratio2.46 Perf Half Y-47.02%
Book/sh11.92 P/B1.36 EPS next Y-10.37% ROA-4.70% Target Price22.50 Perf Year-80.90%
Cash/sh1.91 P/C8.47 EPS next 5Y9.00% ROE-42.90% 52W Range13.00 - 86.50 Perf YTD11.43%
Dividend- P/FCF14.37 EPS past 5Y4.40% ROI3.70% 52W High-81.29% Beta-0.16
Dividend %- Quick Ratio1.10 Sales past 5Y54.60% Gross Margin73.80% 52W Low24.46% ATR0.61
Employees22000 Current Ratio1.50 Sales Q/Q-11.00% Oper. Margin-5.20% RSI (14)60.03 Volatility2.82% 4.04%
OptionableYes Debt/Eq7.31 EPS Q/Q- Profit Margin-22.50% Rel Volume0.73 Prev Close16.58
ShortableYes LT Debt/Eq7.29 EarningsFeb 28 BMO Payout- Avg Volume14.49M Price16.18
Recom3.00 SMA208.10% SMA509.18% SMA200-24.34% Volume10,619,551 Change-2.41%
Feb-14-17Reiterated RBC Capital Mkts Sector Perform $29 → $22
Feb-10-17Reiterated Barclays Equal Weight $34 → $20
Jan-04-17Reiterated Piper Jaffray Underweight $16 → $11
Dec-15-16Downgrade Morgan Stanley Overweight → Equal-Weight $25 → $17
Nov-23-16Downgrade Mizuho Neutral → Underperform $25 → $11
Nov-14-16Reiterated Deutsche Bank Hold $29 → $24
Nov-10-16Reiterated Morgan Stanley Overweight $42 → $25
Nov-10-16Downgrade Rodman & Renshaw Buy → Neutral $81 → $23
Nov-09-16Reiterated RBC Capital Mkts Sector Perform $35 → $29
Oct-14-16Reiterated Deutsche Bank Hold $30 → $29
Oct-12-16Reiterated RBC Capital Mkts Sector Perform $36 → $35
Sep-20-16Resumed Deutsche Bank Hold $30
Aug-17-16Upgrade Morgan Stanley Equal-Weight → Overweight $33 → $42
Aug-15-16Upgrade Mizuho Underperform → Neutral $11 → $25
Aug-10-16Reiterated RBC Capital Mkts Sector Perform $31 → $36
Aug-10-16Reiterated Piper Jaffray Underweight $19 → $22
Aug-09-16Reiterated Rodman & Renshaw Buy $90 → $81
Jun-23-16Downgrade JP Morgan Overweight → Neutral
Jun-08-16Reiterated Stifel Buy $65 → $55
Jun-08-16Reiterated RBC Capital Mkts Sector Perform $58 → $33
Feb-24-17 01:29PM  Sequoia Fund wins dismissal of lawsuit over huge Valeant stake
10:47AM  Valeant's Ugly Earnings History May Repeat Itself at Barrons.com
07:58AM  The Demise Of The Erectile Dysfunction TV Ads at Forbes
Feb-23-17 11:43AM  Former Valeant and Philidor executives plead not guilty in fraud scheme Reuters
11:28AM  Former Valeant and Philidor execs plead not guilty in fraud scheme Reuters
11:07AM  Did 50 Salespeople Leave Valeant? Wells Fargo Investigates at Barrons.com
07:00AM  Obagi Medical Products Announces Collaboration With Suzan Obagi, M.D., And Nextcell Medical To Introduce New Line Of Products PR Newswire
07:00AM  Obagi Medical Products Announces Collaboration With Suzan Obagi, M.D., And Nextcell Medical To Introduce New Line Of Products CNW Group
02:08AM  PRESS DIGEST- New York Times business news - Feb 23 Reuters
Feb-21-17 05:25PM  Tiny Waltham biotech's market cap doubles after $103M Valeant licensing deal at bizjournals.com
03:57PM  Valeant Acquires Eyegate Licensing Rights
11:10AM  Tuesdays Top Biopharma Movers
09:30AM  The Zacks Analyst Blog Highlights: Merck, Valeant Pharmaceuticals International, Allergan, AstraZeneca and Johnson & Johnson
07:44AM  EyeGate Pharma surges 15% on news of Valeant licensing agreement at MarketWatch
07:44AM  EyeGate Pharma surges 15% on news of Valeant licensing agreement
07:30AM  Valeant Pharmaceuticals And EyeGate Enter Into Licensing Agreement For EGP-437 Combination Product In Post-Operative Pain And Inflammation In Ocular Surgery Patients PR Newswire
07:30AM  Valeant Pharmaceuticals And EyeGate Enter Into Licensing Agreement For EGP-437 Combination Product In Post-Operative Pain And Inflammation In Ocular Surgery Patients CNW Group
Feb-20-17 03:40PM  This Guru Loves Valeant; Should You?
01:33PM  [$$] Unilever was a deal too far for Kraft Heinz at Financial Times
Feb-19-17 06:00AM  Sequoia's Foundation Looks Stronger Than It Was Before at Morningstar
Feb-17-17 09:12AM  Valeant's (VRX) Plaque Psoriasis Drug Approved in the U.S.
09:09AM  It Happened Again! Another Drugmaker Got Caught With an Exorbitant Price Hike at Motley Fool
08:05AM  AstraZeneca Stock Rises On Successful Breast Cancer Drug Trial
Feb-16-17 04:41PM  Don't Count on Valeant's New Drug to Save the Day at Motley Fool
01:55PM  Francis Chou Adds to Valeant, Trims Sears in 4th Quarter
01:43PM  Billionaire Bill Ackmans Pershing Square Boosts Bet on Fast Food Industry, Cuts Down on Healthcare at Insider Monkey
12:05PM  Why This FDA Approval for Valeant Is Not as Good as First Thought
11:54AM  New Valeant Approval is a Surprise Irritant at The Wall Street Journal
10:38AM  Valeant Pharmaceuticals: Dead in the Water? at Barrons.com
10:04AM  Stocks to Watch: Kate Spade, MGM Resorts, Avon Products at The Wall Street Journal
09:03AM  Morning Movers: Valeant Jumps, Kate Spade Soars, MGM Drops at Barrons.com
07:22AM  Valeant stock surges 3% after psoriasis drug gets FDA approval at MarketWatch
07:00AM  Valeant Receives FDA Approval Of SILIQ (Brodalumab) For Moderate-To-Severe Plaque Psoriasis PR Newswire
07:00AM  Valeant Receives FDA Approval Of SILIQ (Brodalumab) For Moderate-To-Severe Plaque Psoriasis CNW Group
Feb-15-17 06:37PM  Bill Ackman Expands Chipotle Position, Cuts Zoetis +5.51%
06:34PM  FDA approves Valeant's drug to treat plaque psoriasis Reuters
10:49AM  These 3 Hedge Funds Are Playing With Fire at Motley Fool
10:42AM  Eli Lilly Is Great Stock to Buy Now
Feb-14-17 05:24PM  Ackman boosted Chipotle holdings, pared Valeant in 4th quarter at MarketWatch +6.75%
10:39AM  Valeant: Why $3.75 Billion is the Most Important Number at Barrons.com
09:24AM  Valeant, Pershing Square to Split Legal Fees on Allergan Lawsuit
Feb-13-17 05:00PM  Valeant Pharmaceuticals To Participate At Healthcare Conferences PR Newswire
05:00PM  Valeant Pharmaceuticals To Participate At Healthcare Conferences CNW Group
04:34PM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Feb-10-17 01:58PM  Valeant Pharmaceutcials: I Guess That's Why They Call It 'Equal Weight' at Barrons.com
Feb-09-17 10:49AM  The Important Lesson We Can All Learn From Valeant Pharmaceuticals at Motley Fool
Feb-08-17 09:59AM  Valeant: Another Analyst Cuts Target, Stays Buy Rated Into Earnings at Barrons.com
07:36AM  What Bill Miller Thinks about Valeant Pharmaceuticals
Feb-07-17 12:20PM  Ruane, Cunniff & Goldfarb's Sequoia Fund 4th Quarter Shareholder Letter
10:07AM  Valeant Pharmaceuticals: Worthy of Your Trust? at Barrons.com
08:24AM  Perrigo says it has filed for FDA approval for a generic version of Valeant's acne gel at MarketWatch
Feb-06-17 11:53AM  Valeant Pharmaceuticals: Why This Earnings Report is Really, Really Important at Barrons.com
06:45AM  Why Valeant Pharmaceuticals' Rebound Fizzled at Motley Fool
Feb-03-17 10:23AM  Merck's Sneak Peek Into Its Drug Pricing May Not Be Enough to Satisfy Skeptics at Motley Fool
Feb-02-17 07:36PM  Valeant Short Seller Picks Next Target
07:36PM  Valeant Short Seller Picks Next Target at Bloomberg
09:50AM  7 Stocks You Should Sell Right Now at Kiplinger
Feb-01-17 09:30AM  The Zacks Analyst Blog Highlights: Synergy Pharmaceuticals, Amgen, Valeant Pharmaceuticals International, Celgene and Lexicon Pharmaceuticals
05:00AM  The Short Seller Who Crushed Valeant Has Picked His Next Target at Bloomberg
Jan-31-17 06:43AM  4 FDA Decisions to Watch Out for in Feb 2017
Jan-30-17 04:30PM  Valeant To Hold Conference Call To Present Fourth Quarter And Full Year 2016 Results And Announce 2017 Guidance PR Newswire
04:30PM  Valeant To Hold Conference Call To Present Fourth Quarter And Full Year 2016 Results And Announce 2017 Guidance CNW Group
01:12PM  Is Valeant Pharmaceuticals' Turnaround Finally in the Cards? at Motley Fool
11:16AM  Valeant Pharmaceuticals: A Challenging Setup? at Barrons.com
Jan-27-17 12:49PM  Pershing Square Defends Valeant's Progress, Can't Defend Its Stock Performance
Jan-26-17 12:27PM  Valeant Stock Rises 5% on Possible Asset Sales at Investopedia
09:30AM  Broadcom, Valeant Pharmaceuticals, Apple, Amazon and Netflix highlighted as Zacks Bull and Bear of the Day Broadcom, Valeant Pharmaceuticals, Apple, Amazon and Netflix highlighted as Zacks Bull and Bear of the Day
07:00AM  Bear of the Day: Valeant Pharmaceuticals (VRX)
Jan-24-17 03:46PM  Options Insight: How to Play Valeant
09:16AM  New Strong Sell Stocks for January 24th
Jan-23-17 02:45PM  Analysts dismiss Citron's sour take on TransDigm -5.02%
Jan-21-17 02:42PM  What Will Valeant Pharmaceuticals Sell Off Next? at Motley Fool
02:20PM  A Fond Farewell
Jan-20-17 03:31PM  Short-Seller Andrew Left Says Trump Should Target This Aerospace Stock
12:12PM  Why TransDigm Stock Tumbled 12% Today at Motley Fool
Jan-18-17 04:27PM  Dealpolitik: SEC Tilts Playing Field Against Targets of Hostile Bids at The Wall Street Journal
Jan-17-17 06:19PM  Short Sellers Now Fleeing Valeant Stock at Investopedia
05:49PM  [$$] Allergan Admits to Disclosure Violations During Valeant Bid at The Wall Street Journal
04:44PM  Bill Ackman Eases Into the New Year at Investopedia
07:37AM  Mario Gabelli on Viacom: Potential Growth in the Media Sector
Jan-13-17 04:39PM  Will This Be a Genius or Foolish Move for Johnson & Johnson? at Motley Fool
10:33AM  The strange deal 2 drug makers had over a medicine with a skyrocketing price
06:02AM  Pharma Stock Roundup: Trump Targets Pharma Again, Merck Up on Keytruda News
Jan-12-17 02:35PM  ETFs with exposure to Valeant Pharmaceuticals International, Inc. : January 12, 2017
11:33AM  Is Valeant Pharmaceuticals Intl Inc (VRX) Stock Back From The Dead? at Insider Monkey
10:19AM  Valeant Pharmaceuticals International, Inc. Value Analysis (NYSE:VRX) : January 12, 2017
09:37AM  12 Health Benefits of Medical Marijuana According To Publicly Traded Weed Companies at Insider Monkey
07:35AM  Trump criticism leads to falling stock prices at these Tampa employers at bizjournals.com
07:15AM  Deja Vu for Drug Stocks as Trump Slams Drug Pricing Again
Jan-11-17 04:54PM  Valeant Pharmaceuticals: Separating Fact From Fiction at Motley Fool -6.52%
04:42PM  Valeant Streamlines Portfolio with Skincare Brands Sale
04:21PM  Drug Stocks Tank As Trump Vows To Attack High Drug Prices
03:22PM  Wednesdays Top Biopharma Movers
02:51PM  Valeant's CEO Tries to Pitch Wall Street On the 'New Valeant' Being Very Different
12:40PM  Valeant Pharmaceuticals: Now Comes the Hard Part at Barrons.com
10:15AM  Valeant Pharmaceuticals: 'A Long Road to Recovery' at Barrons.com
09:30AM  Latest Research Reports on Market Movers Valeant Pharmaceuticals and Chipotle Mexican Grill Accesswire
08:40AM  Do Options Traders Know Something About Valeant Pharmaceuticals (VRX) Stock We Don't?
08:15AM  Blog Coverage Valeant Sells-Off Its Skin Care Brands to L'Oreal Accesswire
07:41AM  This Is the Smartest Move Valeant Pharmaceuticals Has Made in a Really Long Time at Motley Fool
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Xifaxan for the treatment of irritable bowel syndrome with diarrhea; Wellbutrin XL for major depressive disorder in adults; Solodyn to treat red and pus-filled pimples of acne in patients, as well as Ziana, Clindagel, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Glumetza to improve glycemic control in adults with type 2 diabetes mellitus; PROVENGE for the treatment of prostate cancer; and Jublia for onychomycosis of the toenails. It also provides Nitropress for the immediate reduction of blood pressure of patients in hypertensive crises; Isuprel for heart related treatments; Xenazine for chorea; Uceris to get ulcerative colitis under control; Lotemax gel for post-operative inflammation and pain; Arestin, a subgingival sustained-release antibiotic; PreserVision, an antioxidant eye vitamin and mineral supplement; CeraVe to rebuild and repair the skin barrier; Biotrue for healthy contact lens wear; and ReNu Multiplus to lubricate and rewet soft contact lenses. In addition, the company offers Ocuvite, a lutein eye vitamin and mineral supplement; Boston, a cleansing solution for gas permeable contact lenses; Artelac to treat dry eyes; various ophthalmic surgical products; SofLens daily disposable contact lenses; Biotrue ONEday lens; Bausch + Lomb Ultra, a contact lens PureVision, a contact lens; and medical device systems for aesthetic applications. Further, it provides Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; Metronidazole to treat bacterial infections; and Latanoprost for the treatment of glaucoma. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September, 2010. The company was founded in 1983 and is based in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ross Thomas W. Sr.DirectorDec 14Buy14.735,00073,65026,822Dec 16 04:19 PM
Pershing Square Capital ManageDirectorDec 12Sale14.853,476,69051,628,84718,114,432Dec 13 04:14 PM
KARABELAS ARGERIS NDirectorAug 11Buy24.654,00098,60020,726Aug 12 04:37 PM
Ross Thomas W. Sr.DirectorJun 13Buy24.404,00097,60021,882Jun 27 03:40 PM
PAPA JOSEPH CCHAIRMAN & CEOJun 10Buy24.48202,0004,944,9602,442,199Jun 13 06:47 AM